Latest Pharma Insights
US Industry Rallies To Meet Rising Demand For Estrogen Patches
The US Association for Accessible Medicines has highlighted the crucial role generic medicines manufacturers are playing in the supply of estrogen patches, for which demand has soared.
Generics Bulletin - October 20, 2026
The US Association for Accessible Medicines has highlighted the crucial role generic medicines manufacturers are playing in the supply of estrogen patches, for which demand has soared.
Generics Bulletin - October 20, 2026
Ambrose Adopts Results-Driven Model To Acquire AM-Pharma
The UK company is buying the Netherlands-based biotech that was once coveted by Pfizer for what could prove to be a bargain.
Scrip - October 20, 2026
The UK company is buying the Netherlands-based biotech that was once coveted by Pfizer for what could prove to be a bargain.
Scrip - October 20, 2026
Nyxoid: Don’t Put Up Pharmacy Access Barriers, Urges Switch Expert Prof. Brass
EMA supports dropping the prescription requirement for Mundipharma’s Nyxoid, but each EU state will decide where it is sold. Eric Brass, former chair of FDA’s Nonprescription Drugs Advisory Committee, warns that routing OTC naloxone through a pharmacist would replace one access barrier with another.
HBW Insight - October 20, 2026
EMA supports dropping the prescription requirement for Mundipharma’s Nyxoid, but each EU state will decide where it is sold. Eric Brass, former chair of FDA’s Nonprescription Drugs Advisory Committee, warns that routing OTC naloxone through a pharmacist would replace one access barrier with another.
HBW Insight - October 20, 2026
MHRA Will ‘Routinely’ Use AI And International Reliance In Assessments By 2030
The UK wants to change the way medtech companies interact with its medical regulator via a more transparent process and greater international collaborations.
Medtech Insight - October 20, 2026
The UK wants to change the way medtech companies interact with its medical regulator via a more transparent process and greater international collaborations.
Medtech Insight - October 20, 2026
Stock Watch: J&J’s Pharma Strength Has Its Limits
Analysts and the press rounded on weak medical device sales in J&J’s third-quarter results, but a deeper dive into its drugs division raised the specters of indication saturation and transient M&A benefits.
Scrip - October 20, 2026
Analysts and the press rounded on weak medical device sales in J&J’s third-quarter results, but a deeper dive into its drugs division raised the specters of indication saturation and transient M&A benefits.
Scrip - October 20, 2026
Amneal Defends Parkinson’s Franchise: Crexont Case Dropped By Sandoz, Rytary Antitrust Suit Advances
A Sandoz patent challenge to Amneal’s Crexont has been voluntarily dismissed without prejudice, but an Alembic suit heads to trial in June 2028. Meanwhile, Rytary faces a separate antitrust class action alleging a suppression of generic competition through an authorized generic deal with Zydus.
Generics Bulletin - October 20, 2026
A Sandoz patent challenge to Amneal’s Crexont has been voluntarily dismissed without prejudice, but an Alembic suit heads to trial in June 2028. Meanwhile, Rytary faces a separate antitrust class action alleging a suppression of generic competition through an authorized generic deal with Zydus.
Generics Bulletin - October 20, 2026
Teva Pushes Back On ‘Politicization’ Of Medicines As UK Organizations Cut Ties
After the UK’s Royal College of Nursing and Royal College of Pharmacy cut ties with Teva, the firm has pushed back by arguing that “healthcare is at its best when it remains focused on patients rather than being politicized.”
Generics Bulletin - October 20, 2026
After the UK’s Royal College of Nursing and Royal College of Pharmacy cut ties with Teva, the firm has pushed back by arguing that “healthcare is at its best when it remains focused on patients rather than being politicized.”
Generics Bulletin - October 20, 2026
Precision Oncology Is Booming, But The Main Routes Are Jammed
Everyone in precision oncology is on the same road. Five targets hold 68% of 511 trials, so the real opportunity lies off the beaten track: novel targets, KRAS beyond G12C and niche subpopulations.
In Vivo - October 20, 2026
Everyone in precision oncology is on the same road. Five targets hold 68% of 511 trials, so the real opportunity lies off the beaten track: novel targets, KRAS beyond G12C and niche subpopulations.
In Vivo - October 20, 2026
Baylink Leverages Claudin 6/9 For Global-First Dual-Targeting ADC Push
Taking aim at both ovarian and lung cancers, China and US-based Baylink is stepping into the arena of antibody-drug conjugates on the back of the unique design of a Claudin-targeting asset, its China president tells Scrip.
Scrip - October 20, 2026
Taking aim at both ovarian and lung cancers, China and US-based Baylink is stepping into the arena of antibody-drug conjugates on the back of the unique design of a Claudin-targeting asset, its China president tells Scrip.
Scrip - October 20, 2026
Ambrose Adopts Results-Driven Model To Acquire AM-Pharma
The UK company is buying the Netherlands-based biotech that was once coveted by Pfizer for what could prove to be a bargain.
Scrip - October 20, 2026
The UK company is buying the Netherlands-based biotech that was once coveted by Pfizer for what could prove to be a bargain.
Scrip - October 20, 2026
Stock Watch: J&J’s Pharma Strength Has Its Limits
Analysts and the press rounded on weak medical device sales in J&J’s third-quarter results, but a deeper dive into its drugs division raised the specters of indication saturation and transient M&A benefits.
Scrip - October 20, 2026
Analysts and the press rounded on weak medical device sales in J&J’s third-quarter results, but a deeper dive into its drugs division raised the specters of indication saturation and transient M&A benefits.
Scrip - October 20, 2026
Baylink Leverages Claudin 6/9 For Global-First Dual-Targeting ADC Push
Taking aim at both ovarian and lung cancers, China and US-based Baylink is stepping into the arena of antibody-drug conjugates on the back of the unique design of a Claudin-targeting asset, its China president tells Scrip.
Scrip - October 20, 2026
Taking aim at both ovarian and lung cancers, China and US-based Baylink is stepping into the arena of antibody-drug conjugates on the back of the unique design of a Claudin-targeting asset, its China president tells Scrip.
Scrip - October 20, 2026
MHRA Will ‘Routinely’ Use AI And International Reliance In Assessments By 2030
The UK wants to change the way medtech companies interact with its medical regulator via a more transparent process and greater international collaborations.
Medtech Insight - October 20, 2026
The UK wants to change the way medtech companies interact with its medical regulator via a more transparent process and greater international collaborations.
Medtech Insight - October 20, 2026
Nyxoid: Don’t Put Up Pharmacy Access Barriers, Urges Switch Expert Prof. Brass
EMA supports dropping the prescription requirement for Mundipharma’s Nyxoid, but each EU state will decide where it is sold. Eric Brass, former chair of FDA’s Nonprescription Drugs Advisory Committee, warns that routing OTC naloxone through a pharmacist would replace one access barrier with another.
HBW Insight - October 20, 2026
EMA supports dropping the prescription requirement for Mundipharma’s Nyxoid, but each EU state will decide where it is sold. Eric Brass, former chair of FDA’s Nonprescription Drugs Advisory Committee, warns that routing OTC naloxone through a pharmacist would replace one access barrier with another.
HBW Insight - October 20, 2026
US Industry Rallies To Meet Rising Demand For Estrogen Patches
The US Association for Accessible Medicines has highlighted the crucial role generic medicines manufacturers are playing in the supply of estrogen patches, for which demand has soared.
Generics Bulletin - October 20, 2026
The US Association for Accessible Medicines has highlighted the crucial role generic medicines manufacturers are playing in the supply of estrogen patches, for which demand has soared.
Generics Bulletin - October 20, 2026
Amneal Defends Parkinson’s Franchise: Crexont Case Dropped By Sandoz, Rytary Antitrust Suit Advances
A Sandoz patent challenge to Amneal’s Crexont has been voluntarily dismissed without prejudice, but an Alembic suit heads to trial in June 2028. Meanwhile, Rytary faces a separate antitrust class action alleging a suppression of generic competition through an authorized generic deal with Zydus.
Generics Bulletin - October 20, 2026
A Sandoz patent challenge to Amneal’s Crexont has been voluntarily dismissed without prejudice, but an Alembic suit heads to trial in June 2028. Meanwhile, Rytary faces a separate antitrust class action alleging a suppression of generic competition through an authorized generic deal with Zydus.
Generics Bulletin - October 20, 2026
Teva Pushes Back On ‘Politicization’ Of Medicines As UK Organizations Cut Ties
After the UK’s Royal College of Nursing and Royal College of Pharmacy cut ties with Teva, the firm has pushed back by arguing that “healthcare is at its best when it remains focused on patients rather than being politicized.”
Generics Bulletin - October 20, 2026
After the UK’s Royal College of Nursing and Royal College of Pharmacy cut ties with Teva, the firm has pushed back by arguing that “healthcare is at its best when it remains focused on patients rather than being politicized.”
Generics Bulletin - October 20, 2026
Precision Oncology Is Booming, But The Main Routes Are Jammed
Everyone in precision oncology is on the same road. Five targets hold 68% of 511 trials, so the real opportunity lies off the beaten track: novel targets, KRAS beyond G12C and niche subpopulations.
In Vivo - October 20, 2026
Everyone in precision oncology is on the same road. Five targets hold 68% of 511 trials, so the real opportunity lies off the beaten track: novel targets, KRAS beyond G12C and niche subpopulations.
In Vivo - October 20, 2026